Original Article
Intussusception among Infants Given an Oral Rotavirus Vaccine
N Engl J Med 2001; 344:564-572February 22, 2001
- Abstract
Background
Intussusception is a form of intestinal obstruction in which a segment of the bowel prolapses into a more distal segment. Our investigation began on May 27, 1999, after nine cases of infants who had intussusception after receiving the tetravalent rhesus–human reassortant rotavirus vaccine (RRV-TV) were reported to the Vaccine Adverse Event Reporting System.
Methods
In 19 states, we assessed the potential association between RRV-TV and intussusception among infants at least 1 but less than 12 months old. Infants hospitalized between November 1, 1998, and June 30, 1999, were identified by systematic reviews of medical and radiologic records. Each infant with intussusception was matched according to age with four healthy control infants who had been born at the same hospital as the infant with intussusception. Information on vaccinations was verified by the provider.
Results
Data were analyzed for 429 infants with intussusception and 1763 matched controls in a case–control analysis as well as for 432 infants with intussusception in a case-series analysis. Seventy-four of the 429 infants with intussusception (17.2 percent) and 226 of the 1763 controls (12.8 percent) had received RRV-TV (P=0.02). An increased risk of intussusception 3 to 14 days after the first dose of RRV-TV was found in the case–control analysis (adjusted odds ratio, 21.7; 95 percent confidence interval, 9.6 to 48.9). In the case-series analysis, the incidence-rate ratio was 29.4 (95 percent confidence interval, 16.1 to 53.6) for days 3 through 14 after a first dose. There was also an increase in the risk of intussusception after the second dose of the vaccine, but it was smaller than the increase in risk after the first dose. Assuming full implementation of a national program of vaccination with RRV-TV, we estimated that 1 case of intussusception attributable to the vaccine would occur for every 4670 to 9474 infants vaccinated.
Conclusions
The strong association between vaccination with RRV-TV and intussusception among otherwise healthy infants supports the existence of a causal relation. Rotavirus vaccines with an improved safety profile are urgently needed.
Media in This Article
Figure 2
Age at the Time of Intussusception.Figure 1
Interval between Vaccination with RRV-TV and Intussusception in 74 Infants.Article Activity
- Article
Rotavirus causes severe gastroenteritis and affects most infants in the United States. There are an estimated 3.5 million cases annually among children less than five years of age in this country, leading to 500,000 office visits, 50,000 hospitalizations, and approximately 20 deaths.1 The morbidity and mortality associated with rotavirus infection are much greater in developing countries.2
In prelicensing trials in the United States, the tetravalent rhesus–human reassortant rotavirus vaccine (RRV-TV; RotaShield, Wyeth Lederle Vaccines, Philadelphia) was 80 percent or more effective in preventing severe rotavirus gastroenteritis in infants.3-5 Although side effects (fever, irritability, decreased appetite, and abdominal cramping) were more common among recipients of RRV-TV three to five days after the first dose than among recipients of placebo, the vaccine was generally well tolerated.6 In 27 prelicensing trials of candidate rotavirus vaccines, 5 cases of intussusception, a rare form of bowel obstruction in which a portion of the bowel prolapses into a more distal portion, were reported among 10,054 infants who received the vaccine (0.05 percent), as compared with 1 case among 4633 recipients of placebo (0.02 percent, P>0.45).7
On August 31, 1998, the Food and Drug Administration approved RRV-TV, which was recommended for use at two, four, and six months of age.4,8 Intussusception was listed as a possible adverse reaction in the manufacturer's product insert and in the published recommendations of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics.4,8 In October 1998, distribution of RRV-TV began. Between this time and May 27, 1999, the Vaccine Adverse Event Reporting System received nine reports of intussusception among infants given RRV-TV, as compared with only four reports overall in the seven years before the introduction of this vaccine. This information prompted the temporary suspension of vaccination against rotavirus and the initiation of a case–control investigation to evaluate the potential association between the vaccine and intussusception.9,10 We report here the results of that case–control investigation.
Methods
The investigation was carried out in the 19 states (California, Georgia, Illinois, Indiana, Maryland, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, and Wisconsin) where 80 percent of the RRV-TV had been distributed, according to the manufacturer. Because the investigation was initiated in response to a public health emergency, it did not require review by an institutional review board at the CDC. Nevertheless, all safeguards for the protection of subjects and the preservation of confidentiality were observed, and oral informed consent was obtained from the parents or guardians of all the infants.
Infants with Intussusception
To select infants with intussusception for the study, we ranked hospitals in the 19 states according to the number of discharge diagnoses of intussusception during the three years before the study period. Hospitals accounting for approximately 75 percent of these discharge diagnoses were selected to provide cases for the study. Infants at these hospitals who had had intussusception were then identified from medical records with the use of a code from the International Classification of Diseases, Ninth Revision (intussusception [560.0]), from logbooks of radiologic procedures, or from medical records with use of Current Procedural Terminology (therapeutic enema for the reduction of intussusception [code 74283], barium enema [74270], or air–contrast barium bowel examination [74280]).
Infants were eligible for the study if they had been hospitalized with intussusception during the study period (November 1, 1998, to June 30, 1999), if they were at least 1 but less than 12 months old at the time of hospitalization, and if the diagnosis had been confirmed by a radiologic procedure, at surgery, or at autopsy. Infants were excluded if the family did not reside in the United States. To preserve the independence of the results, we also excluded infants who were members of the Northern California Kaiser Permanente Medical Group, in which postlicensure surveillance was being conducted for adverse events after vaccination with RRV-TV.9
Controls
Controls were infants born in the same hospital in which the infants with intussusception had been born, with whom they were matched according to age. By matching according to birth hospital and age, we were able to adjust for age, season, and variations in the use of RRV-TV among the different counties and states in the study. A list of infants born on the same day as a given infant with intussusception was generated, and the infants were ranked randomly. Priority for enrollment was then given to the first four infants on the ranked list. If four controls were not available from the first list, additional controls were obtained by generating a randomly ranked list of infants born the day before or the day after the infant with intussusception; this procedure was repeated, if necessary, for a maximum of seven days before or after the birth of the infant with intussusception. Controls were not eligible for the study if they were adopted, had been hospitalized since birth, were the second-born of a pair of twins, or had died or if their parents or guardians did not live in the United States.
Data Collection
Information on each episode of intussusception was abstracted from hospital records. For all the infants, the parents or guardians provided the following information: demographic characteristics, the number of children in the household, the infant's medical and vaccination history, contact information for medical and vaccine providers, type of child care, type of milk used for feeding, and age at the first feeding with solid food other than cereal. For questions regarding the time of events such as vaccination, the reference date was the date of hospitalization (for infants with intussusception) or the date on which the matched control was the same age as the infant with intussusception at the time of hospitalization (for controls). For all infants, the medical providers were interviewed to obtain information on conditions associated with intussusception and on symptoms of illness at visits within two weeks before the reference date and to obtain information regarding all vaccinations, including the date, type, manufacturer, and lot number of each dose. Records of hepatitis B vaccinations at birth hospitals were not sought, and thus results for hepatitis B vaccination are not presented.
Statistical Analysis
Case–Control Analysis
We used univariate and conditional logistic-regression models to estimate the matched odds ratios for intussusception during predefined risk periods within the first 21 days after vaccination (0 to 2, 3 to 14, 3 to 7, 8 to 14, and 15 to 21 days after vaccination).11 In the univariate analyses, variables that differed between the infants with intussusception and the controls at a significance level of P≤0.2 were considered potential confounders and were assessed in the models. Variables that affected the odds ratios for intussusception by approximately 10 percent or more when removed from the analyses were included in the final model.
To determine whether classification of the infants into subgroups according to age or other variables modified the risk of intussusception among infants who received the rotavirus vaccine, we calculated separate odds ratios for each such subgroup (e.g., age subgroups of 1 to 3 months and of 4 to 11 months). Other variables examined in this way were sex, race or ethnic group, type of milk or formula used for feeding, age at the first feeding with solid food, time of administration of a live attenuated poliovirus vaccine (concurrent with or subsequent to the rotavirus vaccine), time of administration of other vaccines, type of child care, number of children in the household younger than five years of age, lot number of each dose of vaccine, gestational age at birth (premature or term), and birth weight (low or normal).
Case-Series Analysis
In the case-series analysis, we examined whether most cases of intussusception occurred shortly after vaccination with RRV-TV or whether they were distributed more uniformly through time. We used a conditional Poisson regression model to estimate the incidence-rate ratios within the predefined risk periods after vaccination, with adjustment for age. Infants with intussusception functioned as their own controls, with implicit adjustment for unrecognized confounders.12 Unvaccinated infants with intussusception were included in the model to adjust for changes in the background incidence of intussusception according to age (in months).
Attributable Fraction
We developed a model to estimate the number of cases of intussusception that would be attributable to RRV-TV, in excess of the background number of cases, if a national program of vaccination were fully implemented. The model assumed a cohort of 3.8 million infants and a 90 percent rate of vaccination with RRV-TV. The ages at which each dose was given were taken from population-based estimates of ages for the primary series of vaccines (diphtheria, tetanus, and whole-cell pertussis or diphtheria, tetanus, and acellular pertussis [Klevens M, CDC: unpublished data]), which were recommended for infants of the same ages as those for the RRV-TV vaccine.
The background incidence rates of intussusception according to month of age were derived from data on cases with a confirmed diagnosis recorded by the Vaccine Safety Datalink project from 1991 to 1997.13 The annualized incidence of intussusception in this data base was 34.2 cases per 100,000 child-years. The adjusted odds ratios derived from the case–control analysis and the incidence-rate ratios derived from the case-series analysis were used to predict the number of cases in excess of the background number that resulted from the administration of RRV-TV during the 21-day period after each dose.
Results
Of 446 eligible infants with intussusception, 429 were included in the case–control analysis. The other 17 infants with intussusception were excluded because information from the parents (13 infants) or medical providers (1 infant) was incomplete or because controls were unavailable (3 infants). Ninety-four percent of the infants with intussusception were matched with at least 4 controls, and a total of 1763 controls had sufficient information for analysis. Seventy-nine percent of the controls who were randomly ranked from 1 to 4 were enrolled. Data from all the controls were included in the results; the results were essentially unchanged when the analyses were restricted to the controls ranked from 1 to 4.
The infants with intussusception and the controls differed significantly with respect to some characteristics. A higher proportion of the infants with intussusception were male and were Hispanic or black. The mother's level of education was lower among these infants; they more often had Medicaid health coverage, and they less often had started consuming solid food before the reference date (Table 1Table 1
Characteristics of the Infants with Intussusception and Their Age-Matched Controls.). Seventy-four of the 429 infants with intussusception (17.2 percent) and 226 of the 1763 controls (12.8 percent) received RRV-TV during the study period (P=0.02). Infants with intussusception and controls who were at least four months old by the end of the study period had similar rates of receipt of a first dose of childhood vaccines other than RRV-TV (diphtheria, tetanus, and whole-cell or acellular pertussis vaccine: 90.8 percent in infants with intussusception and 92.3 percent in controls, P=0.31; poliovirus vaccine: 93.6 percent and 94.0 percent, respectively, P=0.76; and Haemophilus influenzae type b vaccine: 91.9 percent and 93.0 percent, P=0.47).Variables used to adjust the odds ratios were related both to the risk of intussusception (Table 1) and to vaccination with RRV-TV. Variables that were related to vaccination with RRV-TV were examined among the controls. When compared with controls who did not receive RRV-TV, controls who received RRV-TV were more often white (73.8 percent vs. 51.2 percent), more often had private health insurance (82.1 percent vs. 63.6 percent), and more often received inactivated poliovirus vaccine rather than live attenuated poliovirus vaccine (88.2 percent vs. 73.7 percent), and their mothers' level of education was higher (at least college graduation, 44.9 percent vs. 25.6 percent) (P≤0.001 for all comparisons).
Of the 74 infants who had intussusception and who had received RRV-TV, 67 had intussusception after the first, second, or third dose. Most of these 67 cases of intussusception occurred shortly after vaccination (Figure 1Figure 1
Interval between Vaccination with RRV-TV and Intussusception in 74 Infants.). None of the infants with intussusception were hospitalized within two days after vaccination. The clustering of cases was most prominent 3 to 14 days after the first dose (43 cases) and 3 to 14 days after the second dose (9 cases). One infant was hospitalized with intussusception 3 to 14 days after the third dose. Fourteen cases of intussusception occurred more than 14 days after the first, second, or third dose.The risk of intussusception was greatest among infants who were ever vaccinated with RRV-TV and for 3 to 14 days after vaccination (Table 2Table 2
Matched Odds Ratios in the Case–Control Analysis of Intussusception after Vaccination with RRV-TV.). Three to 14 days after vaccination with RRV-TV, the adjusted odds ratio was 10.6 (95 percent confidence interval, 5.7 to 19.6). Three to 14 days after the first dose, the odds ratio was 21.7 (95 percent confidence interval, 9.6 to 48.9), and 3 to 14 days after the second dose, it was 3.3 (95 percent confidence interval, 1.1 to 9.8) (Table 2). Table 3Table 3
Incidence-Rate Ratios in the Case-Series Analysis of Intussusception after Vaccination with RRV-TV. shows the corresponding incidence-rate ratios estimated from the case-series analysis of 432 infants with intussusception who had sufficient data for analysis.We found no evidence that age or other variables, except for feeding with breast milk, modified the risk of intussusception among infants given RRV-TV. The risk of intussusception three to seven days after the first dose of RRV-TV was lower among infants fed breast milk (adjusted odds ratio, 10.7; 95 percent confidence interval, 1.4 to 78.7) than among other vaccinated infants (adjusted odds ratio, 43.3; 95 percent confidence interval, 12.7 to 148.1). However, the difference between these two estimates was not statistically significant (P=0.22).
Infants with intussusception who had received the first or second dose of RRV-TV 14 or fewer days before the onset of this condition were younger than other infants with intussusception (mean age at the time of hospitalization, 4.1 vs. 6.4 months, P<0.001; range, 2.0 to 7.0 vs. 1.0 to 11.0 months) (Figure 2Figure 2
Age at the Time of Intussusception.). The clinical characteristics of the infants vaccinated 14 or fewer days before hospitalization for intussusception were similar to those of other infants with intussusception (need for laparotomy: 23 of 52 [44.2 percent] vs. 208 of 377 [55.2 percent], respectively, P=0.14; need for bowel resection: 8 of 52 [15.4 percent] vs. 67 of 377 [17.8 percent], P=0.67; and lymphoid hyperplasia, 7 of 18 [38.9 percent] vs. 72 of 120 [60.0 percent], P=0.13 and other anatomical masses: 2 of 50 [4.0 percent] vs. 15 of 361 [4.2 percent], P=1.00). No deaths occurred among the infants with intussusception who had received RRV-TV during the preceding 14 days; one death occurred among the other infants with intussusception. The frequency of recurrent intussusception and of serious or chronic health problems did not vary between these recently vaccinated infants and the other infants with intussusception.We estimated that 1291 background cases of intussusception would occur annually in the absence of RRV-TV vaccination. According to the results of our adjusted case–control analysis, if a national program of vaccination with RRV-TV were fully implemented, 361 cases of intussusception attributable to RRV-TV would occur in addition to the 1291 background cases, for an increase of 28.0 percent. According to the results of our case-series analysis, 732 additional cases attributable to intussusception would occur, for an increase of 56.7 percent. The number of infants who would be vaccinated for each case of intussusception that was attributable to RRV-TV would be 9474 according to the case–control results and 4670 according to the case-series results.
Discussion
This study provides evidence of a causal association between RRV-TV and intussusception.14 The association was strong, temporal, and specific. The findings were consistent with the results of a retrospective cohort study of 10 managed-care organizations15 and voluntary reports of cases to the Vaccine Adverse Event Reporting System.16 The size of the odds ratio varied according to dose (first, second, or third) and according to the length of time after vaccination. In the case–control analysis, most of the adjusted odds ratios were higher than the unadjusted odds ratios, indicating the presence of confounding. In the case-series analyses, adjustment for confounding factors was more complete than in the case–control analysis, and the incidence-rate ratios obtained were higher than the adjusted odds ratios.
We found no factor that modified the relation between RRV-TV and intussusception, except perhaps feeding with breast milk. The odds ratio for intussusception was substantially less among RRV-TV–vaccinated infants who were fed breast milk than among RRV-TV–vaccinated infants who were fed other types of milk or formula. Data from prelicensing trials with candidate rotavirus vaccines suggested that replication of RRV-TV is lower among breast-fed infants.3,17,18 Age was not found to modify the effect of RRV-TV on the risk of intussusception, although the statistical power of our study may not have been sufficient to detect differences according to age.
Diagnostic biases or biases due to the availability of information could have affected the results if concern about intussusception had prompted earlier diagnosis in vaccinated infants than in unvaccinated infants or prompted diagnosis of less severe intussusception in vaccinated infants. This is unlikely, however, since the infants with intussusception in our study had a higher rate of surgery and bowel resection than the rates generally reported.19-21 Moreover, medical providers did not appear to associate RRV-TV with intussusception. Almost half of the RRV-TV–vaccinated infants received another dose of RRV-TV after intussusception, and few of the cases of intussusception that occurred within 14 days after vaccination were reported to the Vaccine Adverse Event Reporting System until after the use of RRV-TV was suspended.16 Our study period ended before the use of RRV-TV was suspended.
The pathogenesis of intussusception is not well understood, although an anatomical mass (in lymphatic or other tissue) and abnormal peristalsis have been proposed as contributing factors.22 In our study, lymphoid hyperplasia was inconsistently noted among the infants with intussusception who underwent surgery. Results in a murine model of intussusception23 and anecdotal reports have led to the suggestion that endotoxin and enterotoxins induce transient slowing of peristalsis.24 Wild human rotaviruses, which are detected uncommonly in cases of intussusception,25-27 elaborate an enterotoxin that has age-dependent and dose-dependent functions in humans.28 In mice, the human rotavirus enterotoxin affects the secretion of fluid and electrolytes by activating the enteric nervous system,29 which is also integral to peristalsis.30 The actions of putative enterotoxins derived from strains in the RRV-TV or human strains of rotavirus6,31-34 on the intestinal tract of infants may result in aberrations of peristalsis that affect the probability of intussusception.
Despite the significantly increased risk of intussusception associated with recent RRV-TV vaccination, the annual rate of hospitalization for intussusception attributable to RRV-TV vaccination in a U.S. program would be far lower than the rate of hospitalization attributable to the rotavirus gastroenteritis that is potentially preventable by such vaccination.1,35 Illness and death may result both from wild rotavirus disease and from intussusception related to RRV-TV1 (and Zanardi LR: personal communication), although the net effect of a national program of vaccination with RRV-TV is not known.
In October 1999, the Advisory Committee on Immunization Practices withdrew its recommendation of RRV-TV.36 Important considerations were the desire to limit harm and the perceived low level of severity of most rotavirus infections, since in the United States most complications can be prevented by oral rehydration.37
The morbidity and mortality associated with rotavirus gastroenteritis are much greater in developing countries than in the United States.2 Accordingly, the benefits and the risks of vaccination against rotavirus in developing countries will differ from those in the United States.38 A better understanding of the pathogenesis of intussusception associated with RRV-TV may facilitate decisions regarding the use of RRV-TV in countries where the risk of death due to rotavirus-related illness is high. Rotavirus vaccines with an improved safety profile are urgently needed.
We are indebted to Peter Paradiso, Wendy Stevenson, and Wyeth Lederle Vaccines for data on the distribution of RRV-TV and for their constructive critique of the investigation; to C. Paddy Farrington (Open University, Milton Keynes, England) for discussions about the use of case-series methods in this investigation; to Roger I. Glass and Joseph S. Bresee (CDC) for their helpful comments throughout the investigation; and to the hundreds of people at the CDC and at state and local health departments for their contributions.
Source Information
From the Epidemiology and Surveillance Division (T.V.M., P.M.G., D.B.N., A.O.J., L.R.Z., E.F., C.W.L., M.W., J.R.L.), the Immunization Services Division (M.S.M., S.S.), and the Data Management Division (C.A.O., P.M.G.), National Immunization Program, Centers for Disease Control and Prevention, Atlanta.
Address reprint requests to Dr. Murphy at the Epidemiology and Surveillance Division, National Immunization Program, 1600 Clifton Rd. NE, Mail Stop E-61, Atlanta, GA 30333, or at tvmurphy@cdc.gov.
The members of the Rotavirus Intussusception Investigation Team are listed in the Appendix.
Appendix
The members of the Rotavirus Intussusception Investigation Team were as follows: State and City Health Departments: California State Department of Health Services — K.C. Cummings, A.C. Kimura, C. O'Malley (primary investigator), G. Rothrock, N. Smith, and D.J. Vugia; Chicago Department of Public Health — I. Ramos and U. Samala; Georgia Department of Human Resources, Division of Public Health — K. Arnold (primary investigator), C. Robmann (primary investigator), L. Scott, T. Seegmueller, G. Siebert, and T. Turski; Illinois Department of Public Health — M. Andreasen, D. Bartling, J. Daniels, M.H. Fahrenwald, S. Frederick, J. Girdley, C. Jennings (primary investigator), J.E. Lang, M. Nappi (primary investigator), D. Rowe, and S.W. Smith; Indiana State Department of Health — D. Bixler (primary investigator), J. Butwin, S. Fang, B. Sheets, W. Staggs, and R. Teclaw (primary investigator); Maryland Department of Health and Mental Hygiene — D.M. Dwyer (primary investigator), M.A. Harder, W. Lane, B. Mitchell, J. Roche, S. Schoenfeld, and N. Thayer; Michigan Department of Community Health — J. Blostein, M. Matuck (primary investigator), A. Sorrells, G. Stoltman (primary investigator), and P. Vranesich; Minnesota Department of Health — S. Alcorn, L. Anderson, S. Brenner, K. Como-Sabetti, R. Danila (primary investigator), K. Ehresmann (primary investigator), L. Ehrlich, F. Fong, D. Hiatt, T. Jenkins, R. Kynfield, K. LeDell, C. Lexau, J. Liu, J. Loos, P. Lynch, H. Margellos, C. Miller, C. Olson, J. Rainbow, M. Raymond, K. Russel, B. Sayler, E. Swanson, L. Triden, and K. White; Missouri Department of Health — D. Donnell (primary investigator), F. Kahn, F. Lyndon, H. Marx, M.F. Skala, V. Tomlinson (primary investigator), and M. Warwick (primary investigator); Nebraska Health and Human Services System — C. Allensworth, G. Borden (primary investigator), and T. Safranek (primary investigator); New Jersey Department of Health and Senior Services — K. Aquino, E. Bresnitz (primary investigator), K. Byrd, L. Charland, A. Farrell, L. Franklin, M.P. Gerwel (primary investigator), F. Jennes, D. Lipira, R. Marler, C. O'Donnell (primary investigator), J. Skaling, M. Stanbury, and V.P. Yarmlak; New York State Department of Health — B. Arthur, M. Amyot, B. Anderson, R. Bentowski, B. Bright-Motelson, B. Burke, K. Cardina, R. Colvin, A. Dunham, E. Foster, R. Gioia, A. Grzelecki, S. Hayes, D. Hilfsein, G. McPhee, P. Moran, B. Naizby, M. Newcomb, C. O'Conner-Walker, P. O'Hanlon (primary investigator), J. Ranches, M. Serunkuuma, R. Stiles-Tice, N. Spina, H. Tetley, and C. Waters; New York City Department of Health — N. Bradford, A. Delgado, S. Friedman, R. Gross, C. Hernandez, M. Holland (primary investigator), M. Layton (primary investigator), D. Meyers, B. Mojica, E. Morgan, S. Rubin, A. Seaborough, M. Simmons, and M. Straker; North Carolina Department of Health and Human Services — N. Macormack, A. Pope (primary investigator), B. Rowe-West, K. Ryan, and K. Southwick (primary investigator); Ohio Department of Health — M. DiOrio (primary investigator), E. Koch (primary investigator), and F. Smith; Pennsylvania Department of Public Health — C.M. Baysinger, C. Berringer, P.H. Britz, S. Carlson, P.J. Crawford, J.M. Dormann, A. Gray, R. Groner, D. Hawk, C. Johnson, C. Kuti, A. Ligi, K. Lindahl, P. Lurie (primary investigator), J. Lutz, M. Maron, J. McMahon, S. Miller (primary investigator), P. Montalbano, S. Silvestri, D. Sowa, L.M. Stetson, C. Teacher, S. Thomas, L. Van Parijs, A. Yang, and S.H. Yeager; South Carolina Department of Health and Environmental Control — J. Gibson, J. Iskander (primary investigator), and D. Roberts; Tennessee Department of Health — C. Alexander, D. Arnold, B. Barnes, L. Barnes, J. Bilbro, E. Booth, C. Brady, V. Brinsko, L. Cathey, M.E. Chesser, A.S. Craig (primary investigator), E. Dickey, T. Finke, J. Fowler, L. Gaspard, S. Hall, R.M. Heller, I. Himelright, T. Jones, D. Levine, J. Narramore (primary investigator), J. Painter, K. Shields, S. Slavinski, M. Snowden, T. Spillman, G. Swinger, R. Taylor, and G. Young; Texas Department of Health — D. Evans, A. Friedman, O. Gonzalez, L. Henefy, J. Jackson, R. Jones, C. Kilborn, M.J. Lowrey, D.M. Perrotta (primary investigator), D. Romnes, J. Shultz-Banks, M. Smoot, N. Walae, and B. Walsh; Virginia Health Department — H. Callaway, C. Chandross, A. Colon, A. Cornell, M. Escasenas, A. Greeley, A. Guyet, M. Hemenway, A. Jindal, S. Jones, T. Morgan, R. Nixon, A. Redmond, S. Redmond, B. Rouse, J. Spence, R.B. Stroube, S. Stuckey, L. Vasquez, and D. Woolard (primary investigator); and Wisconsin Department of Health and Family Services — J.P. Davis (primary investigator) and M. Schuknecht. Epidemic Intelligence Service Officers and Preventive Medicine Residents of the CDC (all of whom served as primary or secondary investigators assigned to the state or city indicated): J. Ackelsberg (New York), A. Anderson (Ohio), E. Bancroft (California), L. Barnes (Tennessee), K. Becker (North Carolina), C. Benally (Texas), D.S.B. Blythe (Maryland), R. Burr (Pennsylvania), M. Cortese (Chicago), H. Dao (Indiana), I. Gonzalez (Missouri), L. Hasbrouck (Texas), J. Heffelfinger (New York City), A. Karpati (New Jersey), K. Kohler (Indiana), V. Lamar (Ohio), S. Lister (Pennsylvania), C. Lockett (Michigan), S. Lyss (New York City), K. McDuffie (Texas), S. McLaughlin (South Carolina), F. Mostashari (New York City), T. Naimi (Minnesota), P. Nsubuga (Missouri), J. Perz (Tennessee), E. Quiroz (Ohio), A. Ramsey (Wisconsin), D. Raymond (Michigan), M. Reynolds (Pennsylvania), J. Rooney (Virginia), J. Samuelson (Georgia), S. Santibanez (Nebraska), T. Tiwari (Texas), T.H.F. Tsang (California), A. Uzicanin (New York City), T. Verstraeten (Illinois), M. Wilkins (Michigan), K. Williams (Georgia), and J. Zevallos (Texas). Commissioned Corps, Public Health Advisors, Fellows, Epidemiologists, and Other Staff at the CDC: J. Alexander, J. Alongi, E. Alvarado, L. Boseman, R. Chen, K. Cox, C. Curwick, H. Dang, L.B. Davis, L. Fehrs, E. Finch, L. Galloway, A. Golaz, E. Graves, D. Hamilton, R. Harpaz, C. Hill, C.K. Jalonen, D. Jarvis, M. Kownaski, W. Lasota, R. Nelson, U. Parashar, A. Pelletier, B.A. Prescott, R. Prevots, K. Reed, L. Rodewald, S. Roush, J. Seward, K. Sharp, K. Stout, J. Tuyen, C. Vitek, J. Weisbord, E. West, B. Wilson, E. Yacovone, and L. Zimmerman.
- References
References
1
Glass RI ,Kilgore PE ,Holman RC , et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996;174:Suppl 1:S5-S11
CrossRef | Web of Science | Medline2
Bresee JS ,Glass RI ,Ivanoff B ,Gentsch JR . Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999;17:2207-2222
CrossRef | Web of Science | Medline3
Kapikian AZ ,Flores J ,Hoshino Y , et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a “Jennerian“ approach to vaccination. J Infect Dis 1986;153:815-822
CrossRef | Web of Science | Medline4
Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48:1-20
Medline5
Clemens J ,Keckich N ,Naficy A ,Glass R ,Rao M . Public health considerations for the introduction of new rotavirus vaccines for infants: a case study of tetravalent rhesus rotavirus-based reassortant vaccine. Epidemiol Rev 1999;21:24-42
Web of Science | Medline6
Joensuu J ,Koskenniemi E ,Vesikari T . Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998;17:334-340
CrossRef | Web of Science | Medline7
Rennels MB ,Parashar UD ,Holman RC ,Le CT ,Chang H-G ,Glass RI . Lack of an apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J 1998;17:924-925
CrossRef | Web of Science | Medline8
American Academy of Pediatrics
CrossRef | Web of Science | Medline9
Intussusception among recipients of rotavirus vaccine -- United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999;48:577-581
Medline10
Alpert JJ. PedComm: AAP member alert. Elk Grove Village, Ill.: American Academy of Pediatrics, July 15, 1999.
11
SAS/STAT software: changes and enhancements through release 6.12. Cary, N.C.: SAS Institute, 1997.
12
Farrington CP ,Nash J ,Miller E . Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996;143:1165-1173[Erratum, Am J Epidemiol 1998;147:93.]
Web of Science | Medline13
Chen RT ,DeStefano F ,Davis RL , et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000;78:186-194
Web of Science | Medline14
Rothman KJ, Greenland S. Causation and causal inference. In: Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Philadelphia: Lippincott–Raven, 1998:7-28.
15
Kramarz P, France EK, DeStefano F, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J (in press).
16
Zanard LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System. Pediatrics (in press).
17
Rennels MB . Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996;174:Suppl 1:S107-S111
CrossRef | Web of Science | Medline18
Friedman MG ,Segal B ,Zedaka R , et al. Serum and salivary responses to oral tetravalent reassortant rotavirus vaccine in newborns. Clin Exp Immunol 1993;92:194-199
CrossRef | Web of Science | Medline19
Stringer MD ,Pablot SM ,Brereton RJ . Paediatric intussusception. Br J Surg 1992;79:867-876
CrossRef | Web of Science | Medline20
Orenstein J . Update on intussusception. Contemp Pediatr 2000;17:180, 185-9121
Ein SH ,Alton D ,Palder SB ,Shandling B ,Stringer D . Intussusception in the 1990s: has 25 years made a difference? Pediatr Surg Int 1997;12:374-376
CrossRef | Web of Science | Medline22
Perrin WS ,Lindsay EC . Intussusception: a monograph based on 400 cases. Br J Surg 1921;9:46-71
CrossRef | Web of Science23
Lin Z ,Cohen P ,Nissan A ,Allweis TM ,Freund HR ,Hanani M . Bacterial wall lipopolysaccharide as a cause of intussusception in mice. J Pediatr Gastroenterol Nutr 1998;27:301-305
CrossRef | Web of Science | Medline24
Hemano I ,Hitchens JT ,Beiler JM . Paradoxical intestinal inhibitory effects of staphylococcal enterotoxin. Gastroenterology 1967;53:71-77
Web of Science | Medline25
Konno T ,Suzuki H ,Kutsuzawa T , et al. Human rotavirus infection in infants and young children with intussusception. J Med Virol 1978;2:265-269
CrossRef | Web of Science | Medline26
Mulcahy DL ,Kamath KR ,de Silva LM ,Hodges S ,Carter IW ,Cloonan MJ . A two-part study of the aetiological role of rotavirus in intussusception. J Med Virol 1982;9:51-55
CrossRef | Web of Science | Medline27
Nicolas JC ,Ingrand D ,Fortier B ,Bricout F . A one-year virological survey of acute intussusception in childhood. J Med Virol 1982;9:267-271
CrossRef | Web of Science | Medline28
Ball JM ,Tian P ,Zeng CQY ,Morris AP ,Estes MK . Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996;272:101-104
CrossRef | Web of Science | Medline29
Lundgren O ,Peregrin AT ,Persson K ,Kordasti S ,Uhnoo I ,Svensson L . Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea. Science 2000;287:491-495
CrossRef | Web of Science | Medline30
Stevens RJ ,Publicover NG ,Smith TK . Induction and organization of Ca2+ waves by enteric neural reflexes. Nature 1999;399:62-66
CrossRef | Web of Science | Medline31
Dunn SJ ,Cross TL ,Greenberg HB . Comparison of the rotavirus nonstructural protein NSP1 (NS53) from different species by sequence analysis and northern blot hybridization. Virology 1994;203:178-183
CrossRef | Web of Science | Medline32
Ciarlet M ,Liprandi F ,Conner ME ,Estes MK . Species specificity and interspecies relatedness of NSP4 genetic groups by comparative NSP4 sequence analyses of animal rotaviruses. Arch Virol 2000;145:371-383
CrossRef | Web of Science | Medline33
Offit PA . Host factors associated with protection against rotavirus disease: the skies are clearing. J Infect Dis 1996;174:Suppl 1:S59-S64
CrossRef | Web of Science | Medline34
Ward RL ,Dinsmore AM ,Goldberg G ,Sander DS ,Rappaport RS ,Zito ET . Shedding of rotavirus after administration of the tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 1998;17:386-390
CrossRef | Web of Science | Medline35
Parashar UD ,Holman RC ,Cummings KC , et al. Trends in intussusception-associated hospitalizations and deaths among US infants. Pediatrics 2000;106:1413-1421
CrossRef | Web of Science | Medline36
Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999;48:1007-1007
Medline37
Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis
Web of Science | Medline38
Melton L . Lifesaving vaccine caught in an ethical minefield. Lancet 2000;356:318-318
CrossRef | Web of Science | Medline
- Citing Articles (236)
Citing Articles
1
Jacqueline E Tate, Manish M Patel, Margaret M Cortese, Benjamin A Lopman, Jon R Gentsch, Jessica Fleming, A Duncan Steele, Umesh D Parashar. (2012) Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality. Expert Review of Vaccines 11:2, 211-220
CrossRef2
Jeanne Loughlin, T. Christopher Mast, Michael Doherty, Florence T. Wang, Judy Wong, John D. Seeger. (2012) Post Marketing Evaluation of the Short-term Safety of the Pentavalent Rotavirus Vaccine. The Pediatric Infectious Disease Journal1
CrossRef3
Ronny Kuhnert, Martin Schlaud, Hartmut Hecker. (2011) Evaluation strategies for case series: is Cox regression an alternative to the self controlled case series method for terminal events?. AStA Advances in Statistical Analysis
CrossRef4
E. Miller, J. Stowe. 2011. Vaccine Safety Surveillance. , 603-624.
CrossRef5
Y. G. WELDESELASSIE, H. J. WHITAKER, C. P. FARRINGTON. (2011) Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiology and Infection 139:12, 1805-1817
CrossRef6
Miguel O’Ryan, Yalda Lucero, Alexandre C Linhares. (2011) Rotarix ® : vaccine performance 6 years postlicensure. Expert Review of Vaccines 10:12, 1645-1659
CrossRef7
Escolano, Sylvie, , Farrington, C. Paddy, , Hill, Catherine, , Tubert-Bitter, Pascale, . (2011) Intussusception after Rotavirus Vaccination — Spontaneous Reports. New England Journal of Medicine 365:22, 2139-2139
Full Text8
Pedro L. Moro, Karen Broder, Yenlik Zheteyeva, Natalya Revzina, Naomi Tepper, Dmitry Kissin, Faith Barash, Jorge Arana, Mary D. Brantley, Helen Ding, James A. Singleton, Kimp Walton, Penina Haber, Paige Lewis, Xin Yue, Frank DeStefano, Claudia Vellozzi. (2011) Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. American Journal of Obstetrics and Gynecology 205:5, 473.e1-473.e9
CrossRef9
J. Clemens. (2011) Evaluation of vaccines against enteric infections: a clinical and public health research agenda for developing countries. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2799-2805
CrossRef10
Vesna Blazevic, Suvi Lappalainen, Kirsi Nurminen, Leena Huhti, Timo Vesikari. (2011) Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 29:45, 8126-8133
CrossRef11
S. Elizabeth Williams, Nicola P. Klein, Neal Halsey, Cornelia L. Dekker, Roger P. Baxter, Colin D. Marchant, Philip S. LaRussa, Robert C. Sparks, Jerome I. Tokars, Barbara A. Pahud, Laurie Aukes, Kathleen Jakob, Silvia Coronel, Howard Choi, Barbara A. Slade, Kathryn M. Edwards. (2011) Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009. Vaccine 29:40, 6920-6927
CrossRef12
Satoshi Okimoto, Sumio Hyodo, Miwako Yamamoto, Kazuhiro Nakamura, Masao Kobayashi. (2011) Association of viral isolates from stool samples with intussusception in children. International Journal of Infectious Diseases 15:9, e641-e645
CrossRef13
Osamu Nakagomi, Toyoko Nakagomi. (2011) Rotarix in Japan: Expectations and Concerns. Biologics in Therapy 1:1,
CrossRef14
Rishi Desai, Aaron T. Curns, Manish M. Patel, Umesh D. Parashar. (2011) Trends in Intussusception-Associated Deaths among US Infants from 1979-2007. The Journal of Pediatrics
CrossRef15
Jimmy A Mena, Amine A Kamen. (2011) Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Review of Vaccines 10:7, 1063-1081
CrossRef16
Patel, Manish M.López-Collada, Vesta RichardsonBulhões, Marília MattosDe Oliveira, Lucia HelenaMárquez, Aurora BautistaFlannery, BrendanEsparza-Aguilar, MarcelinoMontenegro Renoiner, Ernesto IsaacLuna-Cruz, María EdiliaSato, Helena KeicoHernández-Hernández, Luz del CarmenToledo-Cortina, GerardoCerón-Rodríguez, MagdalenaOsnaya-Romero, NeydiMartínez-Alcazar, MarioAguinaga-Villasenor, Rocío GabrielaPlascencia-Hernández, ArturoFojaco-González, FranciscoHernández-Peredo Rezk, GuillermoGutierrez-Ramírez, Sixto FortinoDorame-Castillo, RobertoTinajero-Pizano, RogelioMercado-Villegas, BerniceBarbosa, Marilia ReicheltMaluf, Eliane Mara CesárioFerreira, Lucimar Bozzade Carvalho, Francisca Mariados Santos, Ana RosaCesar, Eduardo Dolabellade Oliveira, Maria Elisa PaulaOsterno Silva, Carmem Lúciade los Angeles Cortes, MariaRuiz Matus, CuauhtemocTate, JacquelineGargiullo, PaulParashar, Umesh D.. (2011) Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil. New England Journal of Medicine 364:24, 2283-2292
Full Text17
Andreas Christoph Jenke, Renate Klaaen-Mielke, Matthias Zilbauer, Ulrich Heininger, Hans Trampisch, Stefan Wirth. (2011) Intussusception: Incidence and Treatment—Insights From the Nationwide German Surveillance. Journal of Pediatric Gastroenterology and Nutrition 52:4, 446-451
CrossRef18
J.P. Buttery, M.H. Danchin, K.J. Lee, J.B. Carlin, P.B. McIntyre, E.J. Elliott, R. Booy, J.E. Bines. (2011) Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia. Vaccine 29:16, 3061-3066
CrossRef19
Frances A Justice, Liem T Nguyen, Son N Tran, Carl D Kirkwood, Ngo Thi Thi, John B Carlin, Julie E Bines. (2011) Recurrent intussusception in infants. Journal of Paediatrics and Child Healthno-no
CrossRef20
Ronny Kuhnert, Hartmut Hecker, Christina Poethko-Müller, Martin Schlaud, Mechtild Vennemann, Heather J. Whitaker, C. Paddy Farrington. (2011) A modified self-controlled case series method to examine association between multidose vaccinations and death. Statistics in Medicine 30:6, 666-677
CrossRef21
James E. Crowe. 2011. Prevention of Fetal and Early Life Infections Through Maternal–Neonatal Immunization. , 1212-1230.
CrossRef22
Hyun Ju Oh, Hyun-Sik Kang, Ki Soo Kang, Youn Woo Kim, Jung Yun Hong, Kyung-Sue Shin, Jin Sook Lee, Su Hyun Lee, Keun Hwa Lee, Moonje Cho, Dong In Suh. (2011) Distribution of Disease Severity and Group A Rotavirus Genotypes (VP7 & VP4) in Children with Acute Rotavirus Gastroenteritis. Korean Journal of Pediatric Gastroenterology and Nutrition 14:2, 148
CrossRef23
Marcela F. Pasetti, Jakub K. Simon, Marcelo B. Sztein, Myron M. Levine. (2011) Immunology of gut mucosal vaccines. Immunological Reviews 239:1, 125-148
CrossRef24
Nicolai Bissantz, Andreas C Jenke, Matthias Trampisch, Renate Klaaßen-Mielke, Kathrin Bissantz, Hans-Joachim Trampisch, Tim Holland-Letz. (2011) Hospital-based, prospective, multicentre surveillance to determine the incidence of intussusception in children aged below 15 years in Germany. BMC Gastroenterology 11:1, 26
CrossRef25
Miguel L. O'Ryan, James P. Nataro, Thomas G. Cleary. 2011. Microorganisms Responsible for Neonatal Diarrhea. , 359-418.
CrossRef26
Matthew D. Eberly, Greg H. Gorman, Matilda B. Eide, Cara H. Olsen, Michael Rajnik. (2011) The effect of rotavirus immunization on rotavirus gastroenteritis hospitalization rates in military dependents. Vaccine 29:4, 650-659
CrossRef27
Juan J. Picazo, Javier de Arístegui Fernández, Jose M. Arteagoitia Axpe, Dolores Barranco Ordóñez, Aurelio Barricarte Gurrea, Xavier Bosch José, Javier Díez Domingo, Fernando González Romo, Teresa Hernández-Sampelayo Matos, Jesús Ruiz Contreras, Lluís Salleras. (2011) Evidencias científicas disponibles sobre la seguridad de las vacunas. Vacunas 12:1, 3-34
CrossRef28
Jacqueline E. Tate, Margaret M. Cortese, Daniel C. Payne, Aaron T. Curns, Catherine Yen, Douglas H. Esposito, Jennifer E. Cortes, Benjamin A. Lopman, Manish M. Patel, Jon R. Gentsch, Umesh D. Parashar. (2011) Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States. The Pediatric Infectious Disease Journal 30, S56-S60
CrossRef29
Karen Knipping, Monica M McNeal, Annelies Crienen, Geert van Amerongen, Johan Garssen, Belinda van't Land. (2011) A gastrointestinal rotavirus infection mouse model for immune modulation studies. Virology Journal 8:1, 109
CrossRef30
Lucia Helena de Oliveira, M. Carolina Danovaro-Holliday, N. Jennifer Sanwogou, Cuauhtemoc Ruiz-Matus, Gina Tambini, Jon Kim Andrus. (2011) Progress in the Introduction of the Rotavirus Vaccine in Latin America and the Caribbean. The Pediatric Infectious Disease Journal 30, S61-S66
CrossRef31
Sung Hee Oh. (2011) Trend in Viral Infectious Diseases in Children. Infection and Chemotherapy 43:6, 435
CrossRef32
Mei-Chiung Shih, Tze Leung Lai, Joseph F. Heyse, Jie Chen. (2010) Sequential generalized likelihood ratio tests for vaccine safety evaluation. Statistics in Medicine 29:26, 2698-2708
CrossRef33
Henrik Svanström, Torbjörn Callréus, Anders Hviid. (2010) Temporal Data Mining for Adverse Events Following Immunization in Nationwide Danish Healthcare Databases. Drug Safety 33:11, 1015-1025
CrossRef34
Claudia Vellozzi, Karen R. Broder, Penina Haber, Alice Guh, Michael Nguyen, Maria Cano, Paige Lewis, Michael M. McNeil, Marthe Bryant, James Singleton, David Martin, Frank DeStefano. (2010) Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010. Vaccine 28:45, 7248-7255
CrossRef35
Brian Johnson, Paul Gargiullo, Trudy V Murphy, Umesh D Parashar, Manish M Patel. (2010) Sociodemographic and Dietary Risk Factors for Natural Infant Intussusception in the United States. Journal of Pediatric Gastroenterology and Nutrition 51:4, 458-463
CrossRef36
Keith Grimwood, Stephen B. Lambert, Richard J. Milne. (2010) Rotavirus Infections and Vaccines. Pediatric Drugs 12:4, 235-256
CrossRef37
Bo Zhou, Yongliang Zhang, Xianbing Wang, Jiangli Dong, Bin Wang, Chenggui Han, Jialin Yu, Dawei Li. (2010) Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. Vaccine 28:37, 6021-6027
CrossRef38
Carlos Rodrigo, Nuran Salman, Vladimir Tatochenko, Zsofia Mészner, Carlo Giaquinto. (2010) Recommendations for rotavirus vaccination: A worldwide perspective. Vaccine 28:31, 5100-5108
CrossRef39
Timo Vesikari, Aino Karvonen, Roman Prymula, Volker Schuster, Juan C. Tejedor, Franck Thollot, Pilar Garcia-Corbeira, Silvia Damaso, Htay-Htay Han, Alain Bouckenooghe. (2010) Immunogenicity and safety of the human rotavirus vaccine Rotarix™ co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 28:32, 5272-5279
CrossRef40
Michael Gold, Sarah Dugdale, Richard J Woodman, Kieran A McCaul. (2010) Use of the Australian Childhood Immunisation Register for vaccine safety data linkage. Vaccine 28:26, 4308-4311
CrossRef41
Ivan S. F. Chan, William W. B. Wang, Joseph Heyse. 2010. Vaccine Clinical Trials. , 1402-1415.
CrossRef42
J. Chen, J. F. Heyse, P. Heaton, B. J. Kuter. (2010) Age Dependence of the Risk of Intussusception Following Tetravalent Rhesus-Human Reassortant Rotavirus Tetravalent Vaccine: Is It Beyond Doubt?. American Journal of Epidemiology 171:9, 1046-1054
CrossRef43
Cade M. Nylund, Lee A. Denson, James M. Noel. (2010) Bacterial Enteritis as a Risk Factor for Childhood Intussusception: A Retrospective Cohort Study. The Journal of Pediatrics 156:5, 761-765
CrossRef44
Jacqueline E Tate, Manish M Patel, A Duncan Steele, Jon R Gentsch, Daniel C Payne, Margaret M Cortese, Osamu Nakagomi, Nigel A Cunliffe, Baoming Jiang, Kathleen M Neuzil, Lucia H de Oliveira, Roger I Glass, Umesh D Parashar. (2010) Global impact of rotavirus vaccines. Expert Review of Vaccines 9:4, 395-407
CrossRef45
Ulrich Desselberger, Jim Gray, Mary K. Estes. 2010. Rotaviruses. .
CrossRef46
Stephen C. Hadler, Jane F. Seward. 2010. Immunoprophylaxis of Viral Diseases. .
CrossRef47
Yinyao Lin, Samantha R. Slight, Shabaana A. Khader. (2010) Th17 cytokines and vaccine-induced immunity. Seminars in Immunopathology 32:1, 79-90
CrossRef48
Charlene Wong, Jamie Krashin, Alison Rue-Cover, Mona Saraiya, Elizabeth Unger, Angela Calugar, Lauri Markowitz. (2010) Invasive and In Situ Cervical Cancer Reported to the Vaccine Adverse Event Reporting System (VAERS). Journal of Women's Health 19:3, 365-370
CrossRef49
Evan J Anderson. (2010) Prevention and treatment of viral diarrhea in pediatrics. Expert Review of Anti-infective Therapy 8:2, 205-217
CrossRef50
Melinda Wharton. (2010) Vaccine safety: current systems and recent findings. Current Opinion in Pediatrics 22:1, 88-93
CrossRef51
Madhi, Shabir A., Cunliffe, Nigel A., Steele, Duncan, Witte, Desirée, Kirsten, Mari, Louw, Cheryl, Ngwira, Bagrey, Victor, John C., Gillard, Paul H., Cheuvart, Brigitte B., Han, Htay H., Neuzil, Kathleen M., . (2010) Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. New England Journal of Medicine 362:4, 289-298
Full Text52
Edward A. Belongia, Stephanie A. Irving, Irene M. Shui, Martin Kulldorff, Edwin Lewis, Ruihua Yin, Tracy A. Lieu, Eric Weintraub, W Katherine Yih, Rong Li, James Baggs. (2010) Real-Time Surveillance to Assess Risk of Intussusception and Other Adverse Events After Pentavalent, Bovine-Derived Rotavirus Vaccine. The Pediatric Infectious Disease Journal 29:1, 1-5
CrossRef53
Alexander M. Walker. (2010) Orthogonal predictions: follow-up questions for suggestive data. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef54
Hwa-Gan H. Chang, Perry F. Smith, Bold Tserenpuntsag, Katherine Markey, Umesh Parashar, Dale L. Morse. (2010) Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine. Vaccine 28:3, 754-758
CrossRef55
Chowalit Khumjui, Pawinee Doung-ngern, Tanit Sermgew, Punnarai Smitsuwan, Chuleeporn Jiraphongsa. (2009) Incidence of intussusception among children 0–5 years of age in Thailand, 2001–2006. Vaccine 27, F116-F119
CrossRef56
Manish M Patel, Penina Haber, James Baggs, Patrick Zuber, Julie E Bines, Umesh D Parashar. (2009) Intussusception and rotavirus vaccination: a review of the available evidence. Expert Review of Vaccines 8:11, 1555-1564
CrossRef57
Batmunkh Nyambat, Chhour Y. Meng, Ket Vansith, Un Vuthy, En Rin, Carl Kirkwood, Nada Bogdanovic-Sakran, Paul E. Kilgore. (2009) Hospital-based surveillance for rotavirus diarrhoea in Phnom Penh, Cambodia, March 2005 through February 2007. Vaccine 27, F81-F84
CrossRef58
Anissa Chouikha, Imene Fodha, Kaies Maazoun, Mohamed Ben Brahim, Saida Hidouri, Abdellattif Nouri, Abdelhalim Trabelsi, Andrew Duncan Steele. (2009) Rotavirus infection and intussusception in Tunisian children: implications for use of attenuated rotavirus vaccines. Journal of Pediatric Surgery 44:11, 2133-2138
CrossRef59
Michael J Corbel, Maria de los Angeles Cortes Castillo. (2009) Vaccines and biosimilarity: a solution or a problem?. Expert Review of Vaccines 8:10, 1439-1449
CrossRef60
E. INGLIS, A. KESSON, A. T. NEWALL, K. MACARTNEY, C. R. MacINTYRE. (2009) The burden of rotavirus gastroenteritis in children presenting to a paediatric hospital. Epidemiology and Infection 137:07, 943
CrossRef61
Jeanne Loughlin, Florence T. Wang, Antoine El Khoury, Michael Doherty, T Christopher Mast, John D. Seeger. (2009) Adherence to the Recommended Pentavalent Rotavirus Vaccine Administration Schedule in the United States: 2006–2007. The Pediatric Infectious Disease Journal 28:7, 667-668
CrossRef62
Philipp Agyeman, Daniel Desgrandchamps, Bernard Vaudaux, Christoph Berger, Alessandro Diana, Ulrich Heininger, Claire-Anne Siegrist, Christoph Aebi. (2009) Interpretation of primary care physicians’ attitude regarding rotavirus immunisation using diffusion of innovation theories. Vaccine 27:35, 4771-4775
CrossRef63
W. Katherine Yih, James D. Nordin, Martin Kulldorff, Edwin Lewis, Tracy A. Lieu, Ping Shi, Eric S. Weintraub. (2009) An assessment of the safety of adolescent and adult tetanus–diphtheria–acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 27:32, 4257-4262
CrossRef64
Alison Rue-Cover, John Iskander, Shauna Lyn, Dale R. Burwen, Paul Gargiullo, Sean Shadomy, Joel Blostein, Carolyn B. Bridges, Penina Haber, R. Duane Satzger, Robert Ball, Jane F. Seward. (2009) Death and serious illness following influenza vaccination: a multidisciplinary investigation. Pharmacoepidemiology and Drug Safety 18:6, 504-511
CrossRef65
Joke Bilcke, Philippe Beutels. (2009) Reviewing the Cost Effectiveness of Rotavirus Vaccination. PharmacoEconomics 27:4, 281-297
CrossRef66
M. Aminu, E. A. Ameh, A. Geyer, M. D. Esona, M. B. Taylor, A. D. Steele. (2009) Role of Astrovirus in Intussusception in Nigerian infants. Journal of Tropical Pediatrics 55:3, 192-194
CrossRef67
U. Desselberger, E. Manktelow, W. Li, W. Cheung, M. Iturriza-Gomara, J. Gray. (2009) Rotaviruses and rotavirus vaccines. British Medical Bulletin 90:1, 37-51
CrossRef68
Manish M. Patel, Andrew D. Clark, Roger I. Glass, Harry Greenberg, Jacqueline Tate, Mathuram Santosham, Colin F.B. Sanderson, Duncan Steele, Margaret Cortese, Umesh D. Parashar. (2009) Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: Benefits of mortality reduction versus risk of fatal intussusception. Vaccine 27:22, 2916-2922
CrossRef69
Philippe De Wals, Geneviève Deceuninck, Manale Ouakki, Nicole Boulianne, Gaston De Serres, Lisa Danzig. (2009) Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: Methodological difficulties and imperfect solutions. Vaccine 27:24, 3223-3227
CrossRef70
Gary S. Marshall. (2009) Rotavirus Disease and Prevention Through Vaccination. The Pediatric Infectious Disease Journal 28:4, 351-364
CrossRef71
Shally Awasthi, Girdhar G Agarwal, Vikas Mishra, Vijay Laxmi Nag, Hesham Fathey El Sayed, Antonio Jose Ledo da Cunha, Alvaro Madeiro, Dipty Jain, William M Macharia, James Ndung'u, Saumya Awasthi, Ashish Wakhlu. (2009) Four-country surveillance of intestinal intussusception and diarrhoea in children. Journal of Paediatrics and Child Health 45:3, 82-86
CrossRef72
Brigitte Cheuvart, Leonard R. Friedland, Remon Abu-Elyazeed, Htay Htay Han, Yolanda Guerra, Thomas Verstraeten. (2009) The Human Rotavirus Vaccine RIX4414 in Infants. The Pediatric Infectious Disease Journal 28:3, 225-232
CrossRef73
Richard L. Ward, David I. Bernstein. (2009) Rotarix: A Rotavirus Vaccine for the World. Clinical Infectious Diseases 48:2, 222-228
CrossRef74
Manette T. Niu, Robert Ball, Emily Jane Woo, Dale R. Burwen, Maureen Knippen, M. Miles Braun. (2009) Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990–2007. Vaccine 27:2, 290-297
CrossRef75
Nizar Ajjan. 2009. Acquisitions récentes en matière de vaccinations et vaccins du futur. , 207-301.
CrossRef76
Pramod K Giri, Gopal K Khuller. (2008) Is intranasal vaccination a feasible solution for tuberculosis?. Expert Review of Vaccines 7:9, 1341-1356
CrossRef77
Muhammad Waseem, Henrietta Kotlus Rosenberg. (2008) Intussusception. Pediatric Emergency Care 24:11, 793-800
CrossRef78
Evan J Anderson. (2008) Rotavirus vaccines: viral shedding and risk of transmission. The Lancet Infectious Diseases 8:10, 642-649
CrossRef79
Ricardo Q. Gurgel, Nigel A. Cunliffe, Osamu Nakagomi, Luis E. Cuevas. (2008) Rotavirus genotypes circulating in Brazil before national rotavirus vaccination: A review. Journal of Clinical Virology 43:1, 1-8
CrossRef80
Vladimir Gilca, Chantal Sauvageau, Shelly McNeil, Ian M. Gemmill, Marc Dionne, Simon Dobson, Manale Ouakki, France Lavoie, Bernard Duval. (2008) Setting priorities for new vaccination programs by using public health officers and immunization managers opinions. Vaccine 26:33, 4204-4209
CrossRef81
T.P. Zomer, Y.T.H.P. van Duynhoven, M.J.J. Mangen, N.A.T. van der Maas, H. Vennema, H. Boot, H.E. de Melker. (2008) Assessing the introduction of universal rotavirus vaccination in the Netherlands. Vaccine 26:29-30, 3757-3764
CrossRef82
E.A.S. Nelson, J.S. Bresee, U.D. Parashar, M.-A. Widdowson, R.I. Glass. (2008) Rotavirus epidemiology: The Asian Rotavirus Surveillance Network. Vaccine 26:26, 3192-3196
CrossRef83
David L. McClure, Jason M. Glanz, Stanley Xu, Simon J. Hambidge, John P. Mullooly, James Baggs. (2008) Comparison of epidemiologic methods for active surveillance of vaccine safety. Vaccine 26:26, 3341-3345
CrossRef84
Timo Vesikari, Pierre Van Damme, Carlo Giaquinto, Jim Gray, Jacek Mrukowicz, Ron Dagan, Alfredo Guarino, Hania Szajewska, Vytautas Usonis. (2008) European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Evidence-Based Recommendations for Rotavirus Vaccination in Europe: Executive Summary. Journal of Pediatric Gastroenterology and Nutrition 46:5, 615-618
CrossRef85
Anne Schuchat, Beth P Bell. (2008) Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Expert Review of Vaccines 7:4, 437-456
CrossRef86
N. M. Kiulia, R. Kamenwa, G. Irimu, J. O. Nyangao, Z. Gatheru, A. Nyachieo, A. D. Steele, J. M. Mwenda. (2008) The Epidemiology of Human Rotavirus Associated with Diarrhoea in Kenyan Children: A Review. Journal of Tropical Pediatrics 54:6, 401-405
CrossRef87
Timo Vesikari, Pierre Van Damme, Carlo Giaquinto, Jim Gray, Jacek Mrukowicz, Ron Dagan, Alfredo Guarino, Hania Szajewska, Vytautas Usonis. (2008) European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Evidence-Based Recommendations for Rotavirus Vaccination in Europe. Journal of Pediatric Gastroenterology and Nutrition 46:Suppl 2, S38-S48
CrossRef88
Umesh D Parashar, Roger I Glass. (2008) Rotavirus Vaccination in Europe: The Time Has Finally Arrived. Journal of Pediatric Gastroenterology and Nutrition 46:Suppl 2, S21-S23
CrossRef89
William A. Petri, Mark Miller, Henry J. Binder, Myron M. Levine, Rebecca Dillingham, Richard L. Guerrant. (2008) Enteric infections, diarrhea, and their impact on function and development. Journal of Clinical Investigation 118:4, 1277-1290
CrossRef90
Lucia Helena de Oliveira, M Carolina Danovaro-Holliday, Cuauhtemoc Ruiz Matus, Jon Kim Andrus. (2008) Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Review of Vaccines 7:3, 345-353
CrossRef91
Nathalie Parez. (2008) Rotavirus gastroenteritis: Why to back up the development of new vaccines?. Comparative Immunology, Microbiology and Infectious Diseases 31:2-3, 253-269
CrossRef92
David Greenberg, Noga Givon-Lavi, Nitza Newman, John Wheeler, Zehavi Cohen, Ron Dagan. (2008) Intussusception in Children in Southern Israel. The Pediatric Infectious Disease Journal 27:3, 236-240
CrossRef93
Pavel Isa, Michelle Gutiérrez, Carlos F Arias, Susana López. (2008) Rotavirus cell entry. Future Virology 3:2, 135-146
CrossRef94
Su Eun Park. (2008) Rotavirus Vaccine. Journal of the Korean Medical Association 51:2, 137
CrossRef95
Hanne Vestergaard, Tine Westergaard, Jan Wohlfahrt, Christian Pipper, Mads Melbye. (2008) Association Between Intussusception and Tonsil Disease in Childhood. Epidemiology 19:1, 71-74
CrossRef96
H. Melliez, D. Levybruhl, P.Y. Boelle, B. Dervaux, S. Baron, Y. Yazdanpanah. (2008) Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 26:5, 706-715
CrossRef97
Javier Arístegui. (2008) Vacunas antirrotavirus. Enfermedades Infecciosas y Microbiología Clínica 26, 3-11
CrossRef98
P. M. Heaton, M. Ciarlet. (2007) The Pentavalent Rotavirus Vaccine: Discovery to Licensure and Beyond. Clinical Infectious Diseases 45:12, 1618-1624
CrossRef99
Penelope H. Dennehy, Michelle G. Goveia, Michael J. Dallas, Penny M. Heaton. (2007) The integrated Phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. International Journal of Infectious Diseases 11, S36-S42
CrossRef100
Philippe Lepage, Anne Vergison. (2007) Prevention of childhood rotavirus disease through the use of Rotarix ™ and RotaTeq ™ vaccines. Expert Opinion on Biological Therapy 7:12, 1881-1892
CrossRef101
Monica M. McNeal, Susan C. Stone, Mitali Basu, John D. Clements, Anthony H.-C. Choi, Richard L. Ward. (2007) IFN-γ Is the Only Anti-rotavirus Cytokine Found after In Vitro Stimulation of Memory CD4 + T Cells from Mice Immunized with a Chimeric VP6 Protein. Viral Immunology 20:4, 571-584
CrossRef102
Mathuram Santosham, E. Anthony S. Nelson, Joseph S. Bresee. (2007) Implementing rotavirus vaccination in Asia. Vaccine 25:44, 7711-7716
CrossRef103
Dorothea Sesardic, Sjoerd Rijpkema, Brijesh Prakash Patel. (2007) New adjuvants: EU regulatory developments. Expert Review of Vaccines 6:5, 849-861
CrossRef104
Tracy A. Lieu, Martin Kulldorff, Robert L. Davis, Edwin M. Lewis, Eric Weintraub, Katherine Yih, Ruihua Yin, Jeffrey S. Brown, Richard Platt. (2007) Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events. Medical Care 45:Suppl 2, S89-S95
CrossRef105
Gideon Kersten, Hoang Hirschberg. (2007) Needle-free vaccine delivery. Expert Opinion on Drug Delivery 4:5, 459-474
CrossRef106
Hyun Soo Ko, Jens Peter Schenk, Jochen Tröger, Wiltrud K. Rohrschneider. (2007) Current radiological management of intussusception in children. European Radiology 17:9, 2411-2421
CrossRef107
Stephen B Freedman. (2007) Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy. Expert Opinion on Pharmacotherapy 8:11, 1651-1665
CrossRef108
M.N. Hocine, C.P. Farrington, E. Touzé, H.J. Whitaker, A. Fourrier, T. Moreau, P. Tubert-Bitter. (2007) Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case–control study using the self-controlled case series method. Vaccine 25:31, 5938-5943
CrossRef109
Monica M. McNeal, Mitali Basu, Judy A. Bean, John D. Clements, Anthony H.-C. Choi, Richard L. Ward. (2007) Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice. Virology 363:2, 410-418
CrossRef110
Mohd Azhar Aziz, Shuchi Midha, Syed Mohsin Waheed, Rakesh Bhatnagar. (2007) Oral vaccines: new needs, new possibilities. BioEssays 29:6, 591-604
CrossRef111
J.C. Aguilar, E.G. Rodríguez. (2007) Vaccine adjuvants revisited. Vaccine 25:19, 3752-3762
CrossRef112
FERENC JAKAB, JÁNOS PÉTERFAI, TIBOR VEREBÉLY, EDINA MELEG, KRISZTIÁN BÁNYAI, DOUGLAS K. MITCHELL, GYÖRGY SZÛCS. (2007) Human astrovirus infection associated with childhood intussusception. Pediatrics International 49:1, 103-105
CrossRef113
Miguel O’Ryan. (2007) Rotarix™ (RIX4414): an oral human rotavirus vaccine. Expert Review of Vaccines 6:1, 11-19
CrossRef114
M. Wiese-Posselt, D. Matysiak-Klose, A Gilsdorf, C. Hülße, U. Lindlbauer-Eisenach, . (2007) Rotaviren in Deutschland (2001–2006). Monatsschrift Kinderheilkunde 155:2, 167-175
CrossRef115
Fabio Albano, Eugenia Bruzzese, Antonino Bella, Antonio Cascio, Lucina Titone, Serenella Arista, Giancarlo Izzi, Raffaele Virdis, Paola Pecco, Nicola Principi, Massimo Fontana, Alfredo Guarino. (2007) Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. European Journal of Pediatrics 166:3, 241-247
CrossRef116
Frances A. Justice, Margaret Campo, Nguyen Thanh Liem, Tran Ngoc Son, Tran Phan Ninh, Julie E. Bines. (2007) Accuracy of ultrasonography for the diagnosis of intussusception in infants in Vietnam. Pediatric Radiology 37:2, 195-199
CrossRef117
Sun-Kyoung Park, Young-Sun Heo, Sun-Hye Bing, Doo-Sung Cheon, Jiaqi Chu, Moo-Hyung Jun. (2007) Epidemiological Surveillance of P and G Genotypes of Group A Rotavirus Detected from Diarrheic Patients in Daejeon Region. Journal of Bacteriology and Virology 37:3, 169
CrossRef118
H. Melliez, P.Y. Boelle, S. Baron, Y. Mouton, Y. Yazdanpanah. (2007) Effectiveness of childhood vaccination against rotavirus in sub-Saharan Africa: The case of Nigeria. Vaccine 25:2, 298-305
CrossRef119
Paul M. Gargiullo, Trudy V. Murphy, Robert L. Davis. (2006) Is There a Safe Age for Vaccinating Infants with Tetravalent Rhesus‐Human Reassortant Rotavirus Vaccine?. The Journal of Infectious Diseases 194:12, 1793-1794
CrossRef120
Kenneth J. Rothman, Felix M. Arellano, Yinong Young‐Xu, Lone Simonsen. (2006) Reply to Gargiullo et al.. The Journal of Infectious Diseases 194:12, 1794-1795
CrossRef121
Penelope H. Dennehy, Margaret M. Cortese, Rodolfo E. B??gu??, Jenifer L. Jaeger, Nancy E. Roberts, Rongping Zhang, Philip Rhodes, John Gentsch, Richard Ward, David I. Bernstein, Charles Vitek, Joseph S. Bresee, Mary Allen Staat. (2006) A Case-Control Study to Determine Risk Factors for Hospitalization for Rotavirus Gastroenteritis in U.S. Children. The Pediatric Infectious Disease Journal 25:12, 1123-1131
CrossRef122
Pierre Van Damme, Marie Van der Wielen, Filippo Ansaldi, Daniel Desgrandchamps, Javier Diez Domingo, Francisco Gimenez Sanchez, Jim Gray, Martin Haditsch, Kari Johansen, Paula Lorgelly, Mathie Lorrot, Nathalie Parez, Volkmar Reschke, Markus Rose. (2006) Rotavirus vaccines: considerations for successful implementation in Europe. The Lancet Infectious Diseases 6:12, 805-812
CrossRef123
C. P. Farrington, H. J. Whitaker. (2006) Semiparametric analysis of case series data. Journal of the Royal Statistical Society: Series C (Applied Statistics) 55:5, 553-594
CrossRef124
John C. Galati, Stuart Harsley, Peter Richmond, John B. Carlin. (2006) The burden of rotavirus-related illness among young children on the Australian health care system. Australian and New Zealand Journal of Public Health 30:5, 416-421
CrossRef125
António Roldão, Helena L.A. Vieira, Paula M. Alves, R. Oliveira, Manuel J.T. Carrondo. (2006) Intracellular dynamics in rotavirus-like particles production: Evaluation of multigene and monocistronic infection strategies. Process Biochemistry 41:10, 2188-2199
CrossRef126
Anthony T Newall, Raina MacIntyre, Han Wang, Brynley Hull, Kristine Macartney. (2006) Burden of severe rotavirus disease in Australia. Journal of Paediatrics and Child Health 42:9, 521-527
CrossRef127
Penelope H. Dennehy. (2006) Rotavirus Vaccines: An Update. The Pediatric Infectious Disease Journal 25:9, 839-840
CrossRef128
Robert M. Ward, William E. Benitz, Daniel K. Benjamin, Lillian Blackmon, George P. Giacoia, Mark Hudak, Tamar Lasky, William Rodriguez, Arzu Selen. (2006) Criteria supporting the study of drugs in the newborn. Clinical Therapeutics 28:9, 1385-1398
CrossRef129
Sue D. Xiang, Anja Scholzen, Gabriela Minigo, Cassandra David, Vasso Apostolopoulos, Patricia L. Mottram, Magdalena Plebanski. (2006) Pathogen recognition and development of particulate vaccines: Does size matter?. Methods 40:1, 1-9
CrossRef130
A. Burgener, K. Coombs, M. Butler. (2006) Intracellular ATP and total adenylate concentrations are critical predictors of reovirus productivity from Vero cells. Biotechnology and Bioengineering 94:4, 667-679
CrossRef131
Stanley A. Plotkin. (2006) New Rotavirus Vaccines. The Pediatric Infectious Disease Journal 25:7, 575-576
CrossRef132
Roger I Glass, Umesh D Parashar, Joseph S Bresee, Reina Turcios, Thea K Fischer, Marc-Alain Widdowson, Baoming Jiang, Jon R Gentsch. (2006) Rotavirus vaccines: current prospects and future challenges. The Lancet 368:9532, 323-332
CrossRef133
H Fred Clark, Paul A. Offit, Stanley A. Plotkin, Penny M. Heaton. (2006) The New Pentavalent Rotavirus Vaccine Composed of Bovine (Strain WC3) -Human Rotavirus Reassortants. The Pediatric Infectious Disease Journal 25:7, 577-583
CrossRef134
F. Giménez Sánchez, F. Martinón Torres, E. Bernaola Iturbe, M. Baca Cots, F. de Juan Martín, J. Díez Delgado, M. Garcés Sánchez, J.A. Gómez Campderá, J. Picazo, V. Pineda Solas. (2006) El papel de la vacuna frente a rotavirus en los calendarios de vacunación infantil. Anales de Pediatría 64:6, 573-577
CrossRef135
Umesh D. Parashar, Joseph S. Bresee, Marc-Alain Widdowson, Jon R. Gentsch. (2006) New breath for rotavirus vaccines. Drug Discovery Today: Therapeutic Strategies 3:2, 159-165
CrossRef136
Heather J. Whitaker, C. Paddy Farrington, Bart Spiessens, Patrick Musonda. (2006) Tutorial in biostatistics: the self-controlled case series method. Statistics in Medicine 25:10, 1768-1797
CrossRef137
(2006) Intussusception in the Northern Territory. Journal of Paediatrics and Child Health 42:5, 227-228
CrossRef138
Julie Bines. (2006) Intussusception and rotavirus vaccines. Vaccine 24:18, 3772-3776
CrossRef139
FRANCES A JUSTICE, ALEX W AULDIST, JULIE E BINES. (2006) Intussusception: Trends in clinical presentation and management. Journal of Gastroenterology and Hepatology 21:5, 842-846
CrossRef140
Rosalind J Webby, Julie E Bines, Graeme L Barnes, Helen Tindall, Vicki Krause, Mahomed Patel. (2006) Intussusception in the Northern Territory: The incidence is low in Aboriginal and Torres Strait Islander children. Journal of Paediatrics and Child Health 42:5, 235-239
CrossRef141
(2006) Rotavirus Vaccines. New England Journal of Medicine 354:16, 1747-1751
Full Text142
Kenneth J. Rothman, Yinong Young‐Xu, Felix Arellano. (2006) Age Dependence of the Relation between Reassortant Rotavirus Vaccine (RotaShield) and Intussusception. The Journal of Infectious Diseases 193:6, 898-898
CrossRef143
L. Simonsen, R. J. Taylor, A. Elixhauser, C. Viboud, A. Z. Kapikian. (2006) Reply to Rothman et al.. The Journal of Infectious Diseases 193:6, 898-899
CrossRef144
Timo Vesikari, Aino Karvonen, Bruce D. Forrest, Yasutaka Hoshino, Robert M. Chanock, Albert Z. Kapikian. (2006) Neonatal Administration of Rhesus Rotavirus Tetravalent Vaccine. The Pediatric Infectious Disease Journal 25:2, 118-122
CrossRef145
Angela Liakatos, Milton J. Kiefel, Fiona Fleming, Barbara Coulson, Mark von Itzstein. (2006) The synthesis and biological evaluation of lactose-based sialylmimetics as inhibitors of rotaviral infection. Bioorganic & Medicinal Chemistry 14:3, 739-757
CrossRef146
Vesikari, Timo, Matson, David O., Dennehy, Penelope, Van Damme, Pierre, Santosham, Mathuram, Rodriguez, Zoe, Dallas, Michael J., Heyse, Joseph F., Goveia, Michelle G., Black, Steven B., Shinefield, Henry R., Christie, Celia D.C., Ylitalo, Samuli, Itzler, Robbin F., Coia, Michele L., Onorato, Matthew T., Adeyi, Ben A., Marshall, Gary S., Gothefors, Leif, Campens, Dirk, Karvonen, Aino, Watt, James P., O'Brien, Katherine L., DiNubile, Mark J., Clark, H Fred, Boslego, John W., Offit, Paul A., Heaton, Penny M., . (2006) Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine. New England Journal of Medicine 354:1, 23-33
Full Text147
Ruiz-Palacios, Guillermo M., Pérez-Schael, Irene, Velázquez, F. Raúl, Abate, Hector, Breuer, Thomas, Clemens, SueAnn Costa, Cheuvart, Brigitte, Espinoza, Felix, Gillard, Paul, Innis, Bruce L., Cervantes, Yolanda, Linhares, Alexandre C., López, Pío, Macías-Parra, Mercedes, Ortega-Barría, Eduardo, Richardson, Vesta, Rivera-Medina, Doris Maribel, Rivera, Luis, Salinas, Belén, Pavía-Ruz, Noris, Salmerón, Jorge, Rüttimann, Ricardo, Tinoco, Juan Carlos, Rubio, Pilar, Nuñez, Ernesto, Guerrero, M. Lourdes, Yarzábal, Juan Pablo, Damaso, Silvia, Tornieporth, Nadia, Sáez-Llorens, Xavier, Vergara, Rodrigo F., Vesikari, Timo, Bouckenooghe, Alain, Clemens, Ralf, De Vos, Béatrice, O'Ryan, Miguel, . (2006) Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis. New England Journal of Medicine 354:1, 11-22
Full Text148
Glass, Roger I., Parashar, Umesh D., . (2006) The Promise of New Rotavirus Vaccines. New England Journal of Medicine 354:1, 75-77
Full Text149
Timo Vesikari, Carlo Giaquinto, Hans-Iko Huppertz. (2006) Clinical Trials of Rotavirus Vaccines in Europe. The Pediatric Infectious Disease Journal 25:Supplement, S42-S47
CrossRef150
Philippe Lepage. (2006) Rotavirus Infection in Europe. The Pediatric Infectious Disease Journal 25:Supplement, S5-S6
CrossRef151
Hans-Iko Huppertz, Montse Soriano-Gabarr??, Emmanuel Grimprel, Elisabetta Franco, Zsofia Mezner, Ulrich Desselberger, Yolba Smit, Judith Wolleswinkel-van den Bosch, Beatrice De Vos, Carlo Giaquinto. (2006) Intussusception Among Young Children in Europe. The Pediatric Infectious Disease Journal 25:Supplement, S22-S29
CrossRef152
2006. Rotavirus vaccine. , 3082-3083.
CrossRef153
Miguel L. O’Ryan, James P. Nataro, Thomas G. Cleary. 2006. Microorganisms Responsible for Neonatal Diarrhea. , 603-663.
CrossRef154
N. Reidy, F. O'Halloran, S. Fanning, B. Cryan, Helen O'Shea. (2005) Emergence of G3 and G9 rotavirus and increased incidence of mixed infections in the southern region of Ireland 2001-2004. Journal of Medical Virology 77:4, 571-578
CrossRef155
C.A. Perez, C. Eichwald, O. Burrone, D. Mendoza. (2005) Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. Journal of Applied Microbiology 99:5, 1158-1164
CrossRef156
Joseph S. Bresee, Umesh D. Parashar, Marc-Alain Widdowson, Jon R. Gentsch, A Duncan Steele, Roger I. Glass. (2005) Update on Rotavirus Vaccines. The Pediatric Infectious Disease Journal 24:11, 947-952
CrossRef157
Allen C Cheng, Jay R McDonald, Nathan M Thielman. (2005) Infectious Diarrhea in Developed and Developing Countries. Journal of Clinical Gastroenterology 39:9, 757-773
CrossRef158
Penelope H. Dennehy. (2005) Acute Diarrheal Disease in Children: Epidemiology, Prevention, and Treatment. Infectious Disease Clinics of North America 19:3, 585-602
CrossRef159
Penny M. Heaton, Michelle G. Goveia, Jacqueline M. Miller, Paul Offit, H. Fred Clark. (2005) Development of a Pentavalent Rotavirus Vaccine against Prevalent Serotypes of Rotavirus Gastroenteritis. The Journal of Infectious Diseases 192:s1, S17-S21
CrossRef160
Albert Z. Kapikian, Lone Simonsen, Timo Vesikari, Yasutaka Hoshino, David M. Morens, Robert M. Chanock, John R. La Montagne, Brian R. Murphy. (2005) A Hexavalent Human Rotavirus–Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception. The Journal of Infectious Diseases 192:s1, S22-S29
CrossRef161
E. Anthony S. Nelson, John S. Tam, Joseph S. Bresee, Kin‐Hung Poon, Chi‐Hang Ng, Kin‐Sing Ip, T. Christopher Mast, Paul K.‐S. Chan, Umesh D. Parashar, Tai‐Fai Fok, Roger I. Glass. (2005) Estimates of Rotavirus Disease Burden in Hong Kong: Hospital‐Based Surveillance. The Journal of Infectious Diseases 192:s1, S71-S79
CrossRef162
Frances Justice, John Carlin, Julie Bines. (2005) Changing epidemiology of intussusception in Australia. Journal of Paediatrics and Child Health 41:9-10, 475-478
CrossRef163
K Grimwood. (2005) Unraveling rotaviruses, oral vaccines and intussusception. Journal of Paediatrics and Child Health 41:9-10, 471-472
CrossRef164
L. Simonsen, C. Viboud, A. Elixhauser, R. J. Taylor, A. Z. Kapikian. (2005) More on RotaShield and Intussusception: The Role of Age at the Time of Vaccination. The Journal of Infectious Diseases 192:s1, S36-S43
CrossRef165
Roger I. Glass, Joseph S. Bresee, Reina Turcios, Thea K. Fischer, Umesh D. Parashar, A. Duncan Steele. (2005) Rotavirus Vaccines: Targeting the Developing World. The Journal of Infectious Diseases 192:s1, S160-S166
CrossRef166
Rosabel González, Manuel Franco, Luis Sarmiento, Milagros Romero, Irene Pérez Schael. (2005) Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rotashield™), correlate with protection. Journal of Medical Virology 76:4, 608-612
CrossRef167
Nigel A Cunliffe, Osamu Nakagomi. (2005) A critical time for rotavirus vaccines: a review. Expert Review of Vaccines 4:4, 521-532
CrossRef168
Penelope H. Dennehy, Rebecca C. Brady, Scott A. Halperin, Richard L. Ward, Justin C. Alvey, Francis H. Fischer, Bruce L. Innis, Hal Rathfon, Anne Schuind, Beatrice De Vos. (2005) Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine. The Pediatric Infectious Disease Journal 24:6, 481-488
CrossRef169
Robert L. Davis, Margarette Kolczak, Edwin Lewis, James Nordin, Michael Goodman, David K. Shay, Richard Platt, Steven Black, Henry Shinefield, Robert T. Chen. (2005) Active Surveillance of Vaccine Safety. Epidemiology 16:3, 336-341
CrossRef170
Frank R. Brennan, Gordon Dougan. (2005) Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 23:24, 3210-3222
CrossRef171
S. S. Ellenberg, M. A. Foulkes, K. Midthun, K. L. Goldenthal. (2005) Evaluating the Safety of New Vaccines: Summary of a Workshop. American Journal of Public Health 95:5, 800-807
CrossRef172
Penelope H Dennehy. (2005) Rotavirus vaccines: an update. Current Opinion in Pediatrics 17:1, 88-92
CrossRef173
Janice Yee Chi Lo, Kai Cheung Szeto, Dominic Ngai Chong Tsang, Kwok Hung Leung, Wilina Wei Ling Lim. (2005) Changing epidemiology of rotavirus G-types circulating in Hong Kong, China. Journal of Medical Virology 75:1, 170-173
CrossRef174
Norma Santos, Yasutaka Hoshino. (2005) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Reviews in Medical Virology 15:1, 29-56
CrossRef175
Richard K Zimmerman, Robert M Wolfe, Dwight E Fox, Jake R Fox, Mary Patricia Nowalk, Judith A Troy, Lisa K Sharp. (2005) Vaccine Criticism on the World Wide Web. Journal of Medical Internet Research 7:2, e17
CrossRef176
Thea K. Fischer, Joseph S. Bresee, Roger I. Glass. (2004) Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 22, S49-S54
CrossRef177
Julie E. Bines, Bernard Ivanoff, Frances Justice, Kim Mulholland. (2004) Clinical Case Definition for the Diagnosis of Acute Intussusception. Journal of Pediatric Gastroenterology and Nutrition 39:5, 511-518
CrossRef178
Dorsey Bass. (2004) Case Definition of Intussusception: Use and Misuse. Journal of Pediatric Gastroenterology and Nutrition 39:5, 480-481
CrossRef179
Beatrice De Vos, Timo Vesikari, Alexandre C. Linhares, Bel??n Salinas, Irene P??rez-Schael, Guillermo M. Ruiz-Palacios, Maria de Lourdes Guerrero, Kong Boo Phua, Andr??e Delem, Karin Hardt. (2004) A Rotavirus Vaccine for Prophylaxis of Infants Against Rotavirus Gastroenteritis. The Pediatric Infectious Disease Journal 23:Supplement, S179-S182
CrossRef180
David B. Huang, Jashin J. Wu, Stephen K. Tyring. (2004) A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. Journal of Infection 49:3, 179-209
CrossRef181
F Ra??l Vel??zquez, Guillermina Luna, Roberto Cedillo, Javier Torres, Onofre Mu??oz. (2004) Natural Rotavirus Infection Is Not Associated to Intussusception in Mexican Children. The Pediatric Infectious Disease Journal 23:Supplement, S173-S178
CrossRef182
Derek T. O'Hagan, Rino Rappuoli. (2004) The safety of vaccines. Drug Discovery Today 9:19, 846-854
CrossRef183
Dorsey Bass, Eileen Cordoba, Cornelia Dekker, Anne Schuind, Christopher Cassady. (2004) Intestinal Imaging of Children with Acute Rotavirus Gastroenteritis. Journal of Pediatric Gastroenterology and Nutrition 39:3, 270-274
CrossRef184
T Vesikari, A Karvonen, T Korhonen, M Espo, E Lebacq, J Forster, F Zepp, A Delem, B De Vos. (2004) Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 22:21-22, 2836-2842
CrossRef185
Jean-François Viret, Guido Dietrich, Didier Favre. (2004) Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 22:19, 2457-2469
CrossRef186
D. A. Salmon, L. H. Moulton, N. A. Halsey. (2004) Enhancing Public Confidence in Vaccines Through Independent Oversight of Postlicensure Vaccine Safety. American Journal of Public Health 94:6, 947-950
CrossRef187
Paul Rivest, Mélanie Proulx, Guy Lonergan, Marc H Lebel, Lucie Bédard. (2004) Hospitalisations for gastroenteritis: the role of rotavirus. Vaccine 22:15-16, 2013-2017
CrossRef188
Alberto E Tozzi. (2004) Field evaluation of vaccine safety. Vaccine 22:15-16, 2091-2095
CrossRef189
Ville Postila, Terhi Kilpi. (2004) Use of vaccine surveillance data in the evaluation of safety of vaccines. Vaccine 22:15-16, 2076-2079
CrossRef190
Robert T. Chen. (2004) Evaluation of vaccine safety after the events of 11 September 2001: role of cohort and case-control studies. Vaccine 22:15-16, 2047-2053
CrossRef191
Ian Birch-Machin, Christine A. Newell, Julian M. Hibberd, John C. Gray. (2004) Accumulation of rotavirus VP6 protein in chloroplasts of transplastomic tobacco is limited by protein stability. Plant Biotechnology Journal 2:3, 261-270
CrossRef192
Gagandeep Kang, Miren Iturriza-Gomara, Jeremy G. Wheeler, Premila Crystal, Bindhu Monica, Sasirekha Ramani, Beryl Primrose, Prabhakar D. Moses, Chris I. Gallimore, David W. Brown, Jim Gray. (2004) Quantitation of group A rotavirus by real-time reverse-transcription-polymerase chain reaction: Correlation with clinical severity in children in South India. Journal of Medical Virology 73:1, 118-122
CrossRef193
Ann-Mari Svennerholm, Duncan Steele. (2004) Progress in enteric vaccine development. Best Practice & Research Clinical Gastroenterology 18:2, 421-445
CrossRef194
Xavier Sáez-Llorens, Javier Nieto Guevara. (2004) INTUSSUSCEPTION AND ROTAVIRUS VACCINES: WHAT IS THE BACKGROUND RISK?. The Pediatric Infectious Disease Journal 23:4, 363-365
CrossRef195
M. Sean Kincaid, Monica S. Vavilala, Lee Faucher, Jerry Zimmerman, David Heimbach. (2004) Feeding Intolerance as a Result of Small-Intestine Intussusception in a Child With Major Burns. Journal of Burn Care & Rehabilitation 25:2, 212-214
CrossRef196
Karla Soares-Weiser, Elad Goldberg, Ghandi Tamimi, Leonard Leibovici, Femi Pitan, Karla Soares-Weiser. 2004. Rotavirus vaccine for preventing diarrhoea. .
CrossRef197
Julie E Bines, Katrin S Kohl, Johannes Forster, Lynn R Zanardi, Robert L Davis, John Hansen, Trudy M Murphy, Stanley Music, Mannette Niu, Frederick Varricchio, Patricia Vermeer, Emily J.C Wong. (2004) Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 22:5-6, 569-574
CrossRef198
Paul A Offit, Susan E Coffin. (2003) Communicating science to the public: MMR vaccine and autism. Vaccine 22:1, 1-6
CrossRef199
H. FRED CLARK, CARL J. BURKE, DAVID B. VOLKIN, PAUL OFFIT, RICHARD L. WARD, JOSEPH S. BRESEE, PENELOPE DENNEHY, W. MANFRED GOOCH, EDGARDO MALACAMAN, DAVID MATSON, EMMANUEL WALTER, BARBARA WATSON, DAVID L. KRAH, MICHAEL J. DALLAS, FLORIAN SCH??DEL, KAREN M. KAPLAN, PENNY HEATON. (2003) Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. The Pediatric Infectious Disease Journal 22:10, 914-920
CrossRef200
T.V Nguyen, C Iosef, K Jeong, Y Kim, K.-O Chang, K Lovgren-Bengtsson, B Morein, M.S.P Azevedo, P Lewis, P Nielsen, L Yuan, L.J Saif. (2003) Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs. Vaccine 21:25-26, 4059-4070
CrossRef201
(2003) Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Tropical Medicine and International Health 8:9, 840-846
CrossRef202
MIGUEL O’RYAN, YALDA LUCERO, ALFREDO PEÑA, MARÍA TERESA VALENZUELA. (2003) Two year review of intestinal intussusception in six large public hospitals of Santiago, Chile. The Pediatric Infectious Disease Journal 22:8, 717-721
CrossRef203
Joaquim Gascón, Manuel Corachán. (2003) Aetiology, epidemiology, and management of traveller's diarrhoea. Reviews in Medical Microbiology 14:3, 73-78
CrossRef204
Yasutaka Hoshino, Ronald W Jones, Jerri Ross, Albert Z Kapikian. (2003) Construction and characterization of rhesus monkey rotavirus (MMU18006)- or bovine rotavirus (UK)-based serotype G5, G8, G9 or G10 single VP7 gene substitution reassortant candidate vaccines. Vaccine 21:21-22, 3003-3010
CrossRef205
Jan Holmgren, Cecil Czerkinsky, Kristina Eriksson, Ali Mharandi. (2003) Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21, S89-S95
CrossRef206
Lawrence D. Frenkel, Kimberly Nielsen. (2003) Immunization issues for the 21st century. Annals of Allergy, Asthma & Immunology 90:6, 45-52
CrossRef207
Mohammad Ali, Do Gia Canh, John D Clemens, Jin-Kyung Park, Lorenz von Seidlein, Vu Dinh Thiem, Le Huu Tho, Dang Duc Trach. (2003) The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations. Vaccine 21:15, 1681-1686
CrossRef208
Richard L. Ward. (2003) Possible Mechanisms of Protection Elicited by Candidate Rotavirus Vaccines as Determined with the Adult Mouse Model. Viral Immunology 16:1, 17-24
CrossRef209
IRENE PÉREZ-SCHAEL, MARISOL ESCALONA, BELÉN SALINAS, MERCEDES MATERÁN, MARÍA EGLEÉ PÉREZ, GERMÁN GONZÁLEZ. (2003) Intussusception-associated hospitalization among Venezuelan infants during 1998 through 2001: anticipating rotavirus vaccines. The Pediatric Infectious Disease Journal 22:3, 234-239
CrossRef210
Carl D Kirkwood, Jim Buttery. (2003) Rotavirus vaccines – an update. Expert Opinion on Biological Therapy 3:1, 97-105
CrossRef211
Jan Bonhoeffer, Katrin Kohl, Robert Chen, Philippe Duclos, Harald Heijbel, Ulrich Heininger, Tom Jefferson, Elisabeth Loupi. (2002) The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21:3-4, 298-302
CrossRef212
Kristina Eriksson, Jan Holmgren. (2002) Recent advances in mucosal vaccines and adjuvants. Current Opinion in Immunology 14:5, 666-672
CrossRef213
Yasutaka Hoshino, Ronald W Jones, Robert M Chanock, Albert Z Kapikian. (2002) Generation and characterization of six single VP4 gene substitution reassortant rotavirus vaccine candidates: each bears a single human rotavirus VP4 gene encoding P serotype 1A[8] or 1B[4] and the remaining 10 genes of rhesus monkey rotavirus MMU18006 or bovine rotavirus UK. Vaccine 20:29-30, 3576-3584
CrossRef214
Kathleen M Tatti, Jon Gentsch, Wun-Ju Shieh, Tara Ferebee-Harris, Maureen Lynch, Joseph Bresee, Baoming Jiang, Sherif R Zaki, Roger Glass. (2002) Molecular and immunological methods to detect rotavirus in formalin-fixed tissue. Journal of Virological Methods 105:2, 305-319
CrossRef215
Robert Ball. (2002) Methods of ensuring vaccine safety. Expert Review of Vaccines 1:2, 161-168
CrossRef216
Nigel A. Cunliffe, Joseph S. Bresee, C.Anthony Hart. (2002) Rotavirus Vaccines: Development, Current Issues and Future Prospects. Journal of Infection 45:1, 1-9
CrossRef217
E. A. S. Nelson, John S. Tam, Roger I. Glass, Umesh D. Parashar, Tai Fai Fok. (2002) INCIDENCE OF ROTAVIRUS DIARRHEA AND INTUSSUSCEPTION IN HONG KONG USING STANDARDIZED HOSPITAL DISCHARGE DATA. The Pediatric Infectious Disease Journal 21:7, 701-703
CrossRef218
Liam Smeeth, Laura C. Rodrigues, Andrew J. Hall, Eric Fombonne, Peter G. Smith. (2002) Evaluation of adverse effects of vaccines: the case-control approach. Vaccine 20:19-20, 2611-2617
CrossRef219
Baoming Jiang, Jon R. Gentsch, Roger I. Glass. (2002) The Role of Serum Antibodies in the Protection against Rotavirus Disease: An Overview. Clinical Infectious Diseases 34:10, 1351-1361
CrossRef220
Neal A. Halsey. (2002) Anthrax vaccine and causality assessment from individual case reports. Pharmacoepidemiology and Drug Safety 11:3, 185-187
CrossRef221
John L. Sever, Alan I. Brenner, Arnold D. Gale, Jerry M. Lyle, Lawrence H. Moulton, David J. West. (2002) Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiology and Drug Safety 11:3, 189-202
CrossRef222
Lone Simonsen, David M Morens, William C Blackwelder. (2002) Ecological studies, rotavirus vaccination, and intussusception. The Lancet 359:9311, 1066-1067
CrossRef223
Albert Z Kapikian. (2002) Ecological studies, rotavirus vaccination, and intussusception. The Lancet 359:9311, 1065-1066
CrossRef224
Anthony H. Choi, Monica M. McNeal, Jason A. Flint, Mitali Basu, Nils Y. Lycke, John D. Clements, Judy A. Bean, Heather L. Davis, Michael J. McCluskie, John L. VanCott, Richard L. Ward. (2002) The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine 20:13-14, 1733-1740
CrossRef225
Cristiana Iosef, Trang Van Nguyen, Kwang-il Jeong, Karin Bengtsson, Bror Morein, Yunjeong Kim, Kyeong-Ok Chang, Marli S.P Azevedo, Lijuan Yuan, Paul Nielsen, Linda J Saif. (2002) Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine 20:13-14, 1741-1753
CrossRef226
Nigel A Cunliffe, Joseph S Bresee, Jon R Gentsch, Roger I Glass, C Anthony Hart. (2002) The expanding diversity of rotaviruses. The Lancet 359:9307, 640-641
CrossRef227
EMILY J. CHANG, KENNETH M. ZANGWILL, HANG LEE, JOEL I. WARD. (2002) Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. The Pediatric Infectious Disease Journal 21:2, 97-102
CrossRef228
Murphy, Trudy V., Gargiullo, Paul M., Wharton, Melinda, . (2002) More on Rotavirus Vaccination and Intussusception. New England Journal of Medicine 346:3, 211-212
Full Text229
JOSEPH S. BRESEE, SHAMS EL ARIFEEN, TASNIM AZIM, J. CHAKRABORTY, ANTHONY W. MOUNTS, GOUTAM PODDER, JON R. GENTSCH, RICHARD L. WARD, ROBERT BLACK, ROGER I. GLASS, MOHAMMED YUNUS. (2001) Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh. The Pediatric Infectious Disease Journal 20:12, 1136-1143
CrossRef230
Stuart C. Morrison, Steven J. Czinn. (2001) Portal Vein Gas Associated With Rotavirus Infection. Journal of Pediatric Gastroenterology and Nutrition 33:5, 626-628
CrossRef231
Mackay, Ian R., Rosen, Fred S., , Ada, Gordon, . (2001) Vaccines and Vaccination. New England Journal of Medicine 345:14, 1042-1053
Full Text232
Andrew J Hall. (2001) Ecological studies and debate on rotavirus vaccine and intussusception. The Lancet 358:9289, 1197-1198
CrossRef233
L Simonsen, DM Morens, A Elixhauser, M Gerber, M Van Raden, WC Blackwelder. (2001) Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. The Lancet 358:9289, 1224-1229
CrossRef234
Robert Ball, Leslie K. Ball, Robert P. Wise, M. Miles Braun, Judy A. Beeler, Marcel E. Salive. (2001) STEVENS-JOHNSON SYNDROME AFTER VACCINATION. The Pediatric Infectious Disease Journal 20:8, 819
CrossRef235
(2001) Intussusception and an Oral Rotavirus Vaccine. New England Journal of Medicine 344:24, 1866-1867
Full Text236
PIOTR KRAMARZ, ERIC K. FRANCE, FRANK DESTEFANO, STEVEN B. BLACK, HENRY SHINEFIELD, JOEL I. WARD, EMILY J. CHANG, ROBERT T. CHEN, DEBORAH SHATIN, JERROLD HILL, TRACY LIEU, JOHN M. OGREN. (2001) Population-based study of rotavirus vaccination and intussusception. The Pediatric Infectious Disease Journal 20:4, 410-416
CrossRef
